4.0 Article

International Icodextrin Use and Association with Peritoneal Membrane Function, Fluid Removal, Patient and Technique Survival

Journal

KIDNEY360
Volume 3, Issue 5, Pages 872-882

Publisher

AMER SOC NEPHROLOGY
DOI: 10.34067/KID.0006922021

Keywords

diabetes and the kidney; dialysis modality transfer; icodextrin; patient survival; peritoneal dialysis; peritoneal membrane function

Funding

  1. Baxter Healthcare
  2. Kidney Research UK
  3. National Institutes of Health Research
  4. National Health and Medical Research Council (Australia)
  5. National Institute for Health Research (United Kingdom)
  6. National Institute of Diabetes and Digestive and Kidney Diseases (United States)
  7. Patient-Centered Outcomes Research Institute (United States)
  8. Japanese Society of Peritoneal Dialysis
  9. Canadian Institute for Health Research
  10. Baxter International, Inc (United States)
  11. National Research Council of Thailand [2558-113]
  12. Rachadaphisek-sompot Endorcement Fund, Chulalongkorn University, Thailand [GCURS_59_12_30_03]
  13. National Science and Technology Development Agency (NSTDA), Thailand

Ask authors/readers for more resources

There are significant differences in the prescription of icodextrin internationally, with the United States using it less frequently. Icodextrin prescription is associated with hypertonic glucose avoidance and equivalent ultrafiltration, but not with mortality or permanent transfer to hemodialysis.
Background Icodextrin has been shown in randomized controlled trials to benefit fluid management in peritoneal dialysis (PD). We describe international icodextrin prescription practices and their relationship to clinical outcomes. Methods We analyzed data from the prospective, international PDOPPS, from Australia/New Zealand, Canada, Japan, the United Kingdom, and the United States. Membrane function and 24-hour ultrafiltration according to icodextrin and glucose prescription was determined at baseline. Using an instrumental variable approach, Cox regression, stratified by country, was used to determine any association of icodextrin use to death and permanent transfer to hemodialysis (HDT), adjusted for demographics, comorbidities, serum albumin, urine volume, transplant waitlist status, PD modality, center size, and study phase. Results Icodextrin was prescribed in 1986 (35%) of 5617 patients, .43% of patients in all countries, except in the United States, where it was only used in 17% and associated with a far greater use of hypertonic glucose. Patients on icodextrin had more coronary artery disease and diabetes, longer dialysis vintage, lower residual kidney function, faster peritoneal solute transfer rates, and lower ultrafiltration capacity. Prescriptions with or without icodextrin achieved equivalent ultrafiltration (median 750 ml/d [interquartile range 300-1345 ml/d] versus 765 ml/d [251-1345 ml/d]). Icodextrin use was not associated with mortality (HR51.03; 95% CI, 0.72 to 1.48) or HDT (HR 1.2; 95% CI, 0.92 to 1.57). Conclusions There are large national and center differences in icodextrin prescription, with the United States using significantly less. Icodextrin was associated with hypertonic glucose avoidance but equivalent ultrafiltration, which may affect any potential survival advantage or HDT.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.0
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available